PT  - JOURNAL ARTICLE
AU  - Scheepers, Cathrine
AU  - Everatt, Josie
AU  - Amoako, Daniel G.
AU  - Mnguni, Anele
AU  - Ismail, Arshad
AU  - Mahlangu, Boitshoko
AU  - Wibmer, Constantinos Kurt
AU  - Wilkinson, Eduan
AU  - Tegally, Houriiyah
AU  - San, James Emmanuel
AU  - Giandhari, Jennifer
AU  - Ntuli, Noxolo
AU  - Pillay, Sureshnee
AU  - Mohale, Thabo
AU  - Naidoo, Yeshnee
AU  - Khumalo, Zamantungwa T.
AU  - Makatini, Zinhle
AU  - ,
AU  - Sigal, Alex
AU  - Williamson, Carolyn
AU  - Treurnicht, Florette
AU  - Mlisana, Koleka
AU  - Venter, Marietjie
AU  - Hsiao, Nei-yuan
AU  - Wolter, Nicole
AU  - Msomi, Nokukhanya
AU  - Lessells, Richard
AU  - Maponga, Tongai
AU  - Preiser, Wolfgang
AU  - Moore, Penny L.
AU  - von Gottberg, Anne
AU  - de Oliveira, Tulio
AU  - Bhiman, Jinal N.
TI  - The continuous evolution of SARS-CoV-2 in South Africa: a new lineage with rapid accumulation of mutations of concern and global detection
AID  - 10.1101/2021.08.20.21262342
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.08.20.21262342
4099  - http://medrxiv.org/content/early/2021/08/24/2021.08.20.21262342.short
4100  - http://medrxiv.org/content/early/2021/08/24/2021.08.20.21262342.full
AB  - SARS-CoV-2 variants of interest have been associated with increased transmissibility, neutralization resistance and disease severity. Ongoing SARS-CoV-2 genomic surveillance world-wide has improved our ability to rapidly identify such variants. Here we report the identification of a potential variant of interest assigned to the PANGO lineage C.1.2. This lineage was first identified in May 2021 and evolved from C.1, one of the lineages that dominated the first wave of SARS-CoV-2 infections in South Africa and was last detected in January 2021. C.1.2 has since been detected across the majority of the provinces in South Africa and in seven other countries spanning Africa, Europe, Asia and Oceania. The emergence of C.1.2 was associated with an increased substitution rate, as was previously observed with the emergence of the Alpha, Beta and Gamma variants of concern (VOCs). C.1.2 contains multiple substitutions (R190S, D215G, N484K, N501Y, H655Y and T859N) and deletions (Y144del, L242-A243del) within the spike protein, which have been observed in other VOCs and are associated with increased transmissibility and reduced neutralization sensitivity. Of greater concern is the accumulation of additional mutations (C136F, Y449H and N679K) which are also likely to impact neutralization sensitivity or furin cleavage and therefore replicative fitness. While the phenotypic characteristics and epidemiology of C.1.2 are being defined, it is important to highlight this lineage given its concerning constellations of mutations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Network for Genomic Surveillance South Africa (NGS-SA) is supported by the Strategic Health Innovation Partnerships Unit of the South African Medical Research Council, with funds received from the South African Department of Science and Innovation. Sequencing activities for the different sequencing hubs were provided by a conditional grant from the South African National Department of Health as part of the emergency COVID-19 response, a cooperative agreement between the National Institute for Communicable Diseases of the National Health Laboratory Service and the United States Centers for Disease Control and Prevention (grant number 5 U01IP001048-05-00); the African Society of Laboratory Medicine (ASLM) and Africa Centers for Disease Control and Prevention through a sub-award from the Bill and Melinda Gates Foundation grant number INV-018978; the UK Foreign, Commonwealth and Development Office and Wellcome (Grant no 221003/Z/20/Z); the South African Medical Research Council (Reference number SHIPNCD 76756); the Department of Health and Social Care and managed by the Fleming Fund and performed under the auspices of the SEQAFRICA project; German Federal Ministry of Education and Research (BMBF; grant number 01KA1606; and G7 collaboration grant with the Robert Koch Institute for COVID19) for the African Network for Improved Diagnostics, Epidemiology and Management of common infectious Agents (ANDEMIA). P.L.M. is supported by the South African Research Chairs Initiative of the Department of Science and Innovation and the NRF (Grant No 98341) and the Strategic Health Innovations Program of the SA MRC.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The project was approved by the University of the Witwatersrand Human Research Ethics Committee (HREC) (ref. M180832, M210159, M210752), University of KwaZulu Natal Biomedical Research Ethics Committee (ref. BREC/00001510/2020), Stellenbosch University HREC (ref. N20/04/008_COVID19) and the University of Cape Town HREC (ref. 383/2020) and the University of Pretoria, Faculty of Health human ethics committee, (ref H101_2017). Individual participant consent was not required for the genomic surveillance. This requirement was waived by the Research Ethics Committees.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll of the global SARS-CoV-2 genomes of the C.1.2 lineage generated and presented in this article are publicly accessible through the GISAID platform (https://www.gisaid.org/), along with all other SARS-CoV-2 genomes generated by the NGS-SA. The GISAID accession identifiers of the C.1.2 sequences analyzed in this study are provided as part of Supplementary Tables 2 and 3, which also contain the metadata for the sequences. The nextstrain build of C.1.2 and global sequences will be made available at https://nextstrain.org/groups/ngs-sa. https://www.gisaid.org/